Holmusk closes US$21.5M Series A to build real-world evidence platform for mental health
Holmusk, a data science and healthtech company headquartered in Singapore, announced today it has closed a US$21.5 million funding round, led by US-based Optum Ventures (OV) and Health Catalyst Capital (HCC).
Existing investor Singapore-based Heritas Capital and other unnamed individuals also joined the round.
The new funding round allows Holmusk to expand its US operations in New York City.
A part of the funds will be invested in its proprietary technology to harness and analyse real-world data to accelerate drug development and data-driven medicine.
Founded in 2015, Holmusk aims to transform the lives of people with behavioural health and chronic diseases through evidence-driven medicine. It is building a real-world evidence platform for mental health and chronic diseases.
This is made possible by bringing together specialty behavioural health data and Holmusk’s novel analytics platform to deliver evidence-based insight that care providers, healthcare payers and patients can use to make fully informed care and treatment decisions, and better integrate care for people with both behavioral and chronic health needs.
These capabilities can also aid pharma companies with R&D and commercialisation of new drugs.
In 2016, Holmusk acquired MindLinc, an electronic health record (EHR) system focused on behavioural health, from Duke University School of Medicine. This enabled the company to leverage longitudinal data from many mental health institutions across US, stretching over 20 years.
Holmusk has offices in New York City, London and Shanghai.